Instead of a broad launch targeting primary care, Madrigal focused its specialty sales force on the 315,000 patients already diagnosed with moderate-to-severe MASH. This disciplined approach of targeting a specific, existing patient population allowed for efficient market penetration and rapid success.

The CEO predicts the future of Duchenne muscular dystrophy treatment will involve combination therapy. Rather than one gene therapy replacing all other drugs, he expects a future where gene therapies are used alongside exon-skipping drugs. Payer research indicates willingness to cover both if the gene therapy shows at least three years of durability.

Instead of building new sales teams for each product, Biocon maintains highly trained, specialized commercial teams focused on four core therapeutic areas: oncology, ophthalmology, immunology, and diabetes. This allows the company to efficiently launch new products within these pillars, leveraging existing expertise and infrastructure for scalable and repeatable commercial success.

Priovant strategically focuses on rare autoimmune diseases affecting tens of thousands of patients, rather than ultra-rare conditions. This approach addresses significant unmet needs while creating a substantial cumulative market opportunity by aggregating multiple such indications.

In the rare disease space, success hinges on deep patient community engagement. Smaller, nimbler biotechs often excel at creating these essential personal ties, giving them a significant advantage over larger pharmaceutical companies.

The company's plan to commercialize its drug alone is based on the manageable scale of CML clinical trials. Unlike mass-market diseases like obesity, pivotal trials require only 250-400 patients, making the financial and operational burden feasible for a smaller company to handle without a larger partner.

Instead of raising large sums to hire a direct sales force, SmallTap partnered with regional specialty distributors. This strategy minimized equity dilution and leveraged existing sales relationships for broad market access without the high fixed costs of full-time employees.

Regeneron pursues therapies for ultra-rare diseases, even without a clear standalone business model. The strategy is to treat these programs as the "tip of the iceberg," establishing a technology platform and biological understanding that can then be expanded to treat much more common diseases.

Developing drugs for rare diseases demands a hands-on, dedicated approach. Unlike mass-market trials, it involves deep partnerships with busy academic centers and requires a company culture entirely focused on the unique, high-touch challenges of the space.